Keppra and Tukysa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keppra and Tukysa. Common interactions include diarrhoea among females.

The phase IV clinical study analyzes what interactions people who take Keppra and Tukysa have. It is created by eHealthMe based on reports of 34 people who take Keppra and Tukysa from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

34 people who take Keppra and Tukysa together, and have interactions are studied.


What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 66,524 Keppra users for its effectiveness, alternative drugs and more.

What is Tukysa?

Tukysa has active ingredients of tucatinib. eHealthMe is studying from 2,340 Tukysa users for its effectiveness, alternative drugs and more.

Number of Keppra and Tukysa reports submitted per year:

Keppra and Tukysa drug interactions.

Common Keppra and Tukysa drug interactions by gender *:

female:

  1. Diarrhoea
  2. Palmar-plantar erythrodysaesthesia syndrome
  3. Photosensitivity reaction
  4. Skin hypertrophy
  5. Memory impairment
  6. Administration site pain
  7. Constipation
  8. Dizziness
  9. Decreased appetite
  10. Erythema

male:

n/a

Common Keppra and Tukysa drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Hypoaesthesia
  2. Somnolence
  3. Amnesia
  4. Constipation
  5. Dizziness
  6. Fatigue
  7. Headache
  8. Metastasis
  9. Erythema
  10. Gait disturbance

40-49:

  1. Diarrhoea
  2. Fatigue
  3. Hypokalaemia
  4. Soft tissue infection
  5. Syncope
  6. Asthenia
  7. Decreased appetite
  8. Fall
  9. Haematocrit decreased
  10. Haemoglobin decreased

50-59:

  1. Neuropathy peripheral
  2. Palmar-plantar erythrodysaesthesia syndrome
  3. Peripheral swelling
  4. Stomatitis
  5. Colitis
  6. Decreased appetite
  7. Diarrhoea
  8. Fatigue
  9. Haematochezia
  10. Thrombocytopenia

60+:

  1. Catatonia
  2. Decreased appetite
  3. Dysphagia
  4. Erythema
  5. Fall
  6. Vomiting

Common conditions people have *:

  1. Breast Cancer Female: 18 people, 52.94%
  2. Breast Cancer: 10 people, 29.41%
  3. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and Tukysa?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Keppra and Tukysa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Keppra interactions:

Browse all interactions between Keppra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam and tucatinib (the active ingredients of Keppra and Tukysa, respectively), and Keppra and Tukysa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Keppra and Tukysa.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: